Practice guidelines for diseases caused by Aspergillus

Clinical Infectious Diseases

Volumn 30, Issue 4, 2000, Pages 696-709

  Stevens, David A ^a,b,g   Kan, Virginia L ^c,g   Judson, Marc A ^d,g   Morrison, Vicki A ^e,k   Dummer, Stephen ^f,g   Denning, David W ^a,c,l   Bennett, John E ^g   Walsh, Thomas J ^g,h   Patterson, Thomas F ^g,i   Pankey, George A ^g,j  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j OCHSNER CLINIC FOUNDATION   (United States)

^k Cancer and Leukemia Group B   (United States)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (4 CYANOPHENYL) 2 THIAZOLYL] 2 (2,4 DIFLUOROPHENYL) 1 (1H 1,2,4 TRIAZOL 1 YL) 2 BUTANOL; 4 [4 [4 [4 [[5 (2,4 DIFLUOROPHENYL)TETRAHYDRO 5 (1H 1,2,4 TRIAZOL 1 YLMETHYL) 3 FURYL]METHOXY]PHENYL] 1 PIPERAZINYL]PHENYL] 2,4 DIHYDRO 2 (1 ETHYL 2 HYDROXYPROPYL) 3H 1,2,4 TRIAZOL 3 ONE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN B DERIVATIVE; FK 463; IMMUNOGLOBULIN E; ITRACONAZOLE; L 743872; LY 303366; NYSTATIN; POSACONAZOLE; PREDNISONE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ARTERY EMBOLISM; ASPERGILLOSIS; ASPERGILLUS; BRONCHOPULMONARY ASPERGILLOMA; CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; EAR INFECTION; EYE INFECTION; HEMOPTYSIS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LUNG ASPERGILLOSIS; LUNG SURGERY; MORBIDITY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RATING SCALE; REVIEW; THORAX RADIOGRAPHY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; HUMAN; LUNG DISEASES, FUNGAL;

EID: 0033801039     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313756     Document Type: Review

References (202)

1. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
2. Aspergillus infection complicating cardiac transplantation
3. Favorable outcome of invasive aspergillosis in patients with acute leukemia
4. Antifungal and surgical treatment of invasive aspergillosis: Review of 2121 published cases
5. Lipid formulations of amphotericin B: Recent progress and future directions
6. Amphotericin B lipid complex in patients with invasive fungal infections: Analysis of safety and efficacy in 556 cases
7. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses
8. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant
9. Efficacy of amphotericin B encapsulated in liposomes (Am Bisome) in the treatment of invasive fungal infections in immunocompromised patients
10. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: A single-centre experience of 133 episodes in 116 patients
11. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections
12. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis
13. Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis
14. Analysis of compassionate use itraconazole for invasive aspergillosis by the NIAID Mycoses Study Group criteria
15. Treatment of invasive aspergillosis with itraconazole
16. Experience with itraconazole in deep mycoses in northern Italy
17. Itraconazole therapy in aspergillosis: Study in 49 patients
18. The treatment of aspergillosis and aspergilloma with itraconazole: Clinical results of an open international study (1982-1987)
19. The interaction of azoles with rifampin, phenytoin and carbamazepine: In vitro and clinical observations
20. Effect of cyclodextrin on the pharmacology of antifungal oral azoles
21. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers
22. Itraconazole in cyclodextrin solution
23. Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia
24. Fungal infections in chronic granulomatous disease: The importance of the phagocyte in defense against fungi
25. The spectrum of non-Candida fungal infections following bone marrow transplantation
26. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
27. Clinical aspects of fungal infection in organ transplant recipients
28. Pulmonary aspergillosis in the acquired immunodeficiency syndrome
29. Pulmonary aspergillosis: Early diagnosis improves survival
30. Aspergillus fungemia: Report of two cases and review
31. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis: Results from a three-year prospective study
32. The use of respiratory tract cultures in the diagnosis of invasive aspergillosis
33. The spectrum of pulmonary aspergillosis
34. Aspergillosis: A disease with many faces
35. Invasive pulmonary aspergillosis in acute leukemia: Characteristic findings on CT, the CT halo sign and the role of CT in early diagnosis
36. The role of bronchoalveolar lavage in the diagnosis of invasive pulmonary aspergillosis
37. The value of bronchoalveolar lavage and bronchial washings in the diagnosis of invasive pulmonary aspergillosis
38. Serodiagnosis and monitoring of Aspergillus infections after lung transplantation
39. Value of antigen detection in predicting invasive pulmonary aspergillosis
40. Aspergillus antigen detection in the diagnosis of invasive aspergillosis
41. Detection of Aspergillus antigens associated with invasive infection
42. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of aspergillosis
43. Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients
44. Prospective sandwich enzyme-linked immunosorbent assays for serum galactomannan: Early predictive value and clinical use in invasive aspergillosis
45. General primer-mediated PCR for detection of Aspergillus species
46. Detection and identification of fungal pathogens in blood by using molecular probes
47. Detection of Apergillus species DNA in bronchoalveolar samples by competitive PCR
48. Detection of Aspergillus fumigatus by polymerase chain reaction
49. Plasma (1,3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes
50. The application of serum mannitol determinations for the diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients
51. Therapeutic outcome in invasive aspergillosis
52. In vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis
53. An EORTC international multicenter randomized trial (EORTC no. 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
54. The efficacy and tolerability of UK-109,496 (voriconazole) in the treatment of invasive aspergillosis
55. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents
56. Amphotericin B refractory aspergillosis after itraconazole: Evidence for significant antagonism
57. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery
58. Fatal haemoptysis in pulmonary filamentous mycosis: An underevaluated cause of death in patients with acute leukemia in hematological complete remission: A retrospective study and review of the literature
59. Combination immunotherapy and antifungal chemotherapy
60. Granulocyte transfusions: Efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation
61. Granulocyte transfusion therapy in chronic granulomatous disease: Report of a patient and review of the literature
62. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor after remission induction chemotherapy in children with acute lymphocytic leukemia
63. Use of macrophage colony-stimulating factor in the treatment of fungal infections
64. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies
65. Treatment of acute myeloid leukemia with cytokines: Effect on duration of neutropenia and response to infections
66. Recombinant human interferon-γ as adjunct therapy for Aspergillus infection in a patient with chronic granulomatous disease
67. Fungal sinusitis
68. Fungal sinusitis in immunocompromised children with neoplasms
69. Invasive mold sinusitis: 17 Cases in immunocompromised patients and review of the literature
70. Functional endoscopic sinus surgery in the immunocompromised child
71. Aspergillosis of the maxillary sinus in a patient with Ph1 positive acute lymphoblastic leukemia: A case report
72. Aspergillus sinusitis
73. Aspergilloma of paranasal sinuses - A common cause of unilateral proptosis in Sudan
74. Aspergilloma of sinus
75. Endoscopic surgery for mycotic and chronic recurring sinusitis
76. Aspergillosis of the orbit. Report of ten cases and review of the literature
77. Aspergilloma of paranasal sinuses and orbit in a northern Sudanese
78. Chronic fungal sinusitis in apparently normal hosts
79. Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS
80. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: Report of 33 cases
81. Pulmonary aspergillosis in patients with AIDS
82. Aspergillus laryngotracheobronchitis presenting as stridor in a patient with peripheral T cell lymphoma
83. Successful treatment of invasive bronchial aspergillosis after single-lung transplantation
84. Ulcerative tracheobronchitis after lung transplantation
85. Aspergillus epiglottitis
86. Tracheobronchial aspergillosis in a patient with AIDS treated with aerosolized amphotericin B combined with itraconazole
87. Necrotizing otitis externa due to Aspergillus in an immunocompetent host
88. Atypical invasive external otitis from Aspergillus
89. Malignant external otitis due to Aspergillus flavus with fulminant dissemination to the lungs
90. Endogenous Aspergillus endophthalmitis
91. Successful treatment of exogenous Aspergillus endophthalmitis: A case report
92. Pars plana vitrectomy in the management of endogenous Candida endophthalmitis
93. Aspergillus endocarditis in children: Case report and review of the literature
94. Orbital aspergillosis: Conservative debridement and local amphotericin irrigation
95. A fungal infection as an intrascleral abscess
96. Bilateral endogenous necrotizing scleritis due to Aspergillus oryzae
97. The use of collagen shields impregnated with amphotericin B to treat aspergillosis keratomycosis
98. Topical ketoconazole for fungal keratitis
99. Clotrimazole in the treatment of ocular infection by Aspergillus fumigatus
100. Severe Aspergillus keratomycosis treated with itraconazole per os
101. Mycotic keratitis - An underestimated mycosis
102. Aspergillus infections of the central nervous system: A clinicopathological analysis
103. Aspergillosis: The spectrum of the disease in 98 patients
104. Cerebral aspergillosis: Report of two cases
105. Successful treatment of pulmonary and cerebral aspergillosis in an immunosuppressed child
106. Stereotactic drainage of Aspergillus brain abscess with long-term survival: Case report and review
107. Invasive central nervous system aspergillosis: Cure with liposomal amphotericin B, itraconazole, and radical surgery - Case report and review of the literature
108. Oral treatment with itraconazole of aspergilloma in cavitary lung cancer
109. Treatment of cerebral aspergillosis with itraconazole: Do high doses improve the prognosis?
110. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia
111. Aspergillus infection complicating transsphenoidal yttrium-90 pituitary implant
112. Aspergillus meningitis: Diagnosis by nonculture-based microbiological methods and management
113. Aspergillus meningitis in an immunocompetent adult successfully treated with itraconazole
114. Aspergillosis infection in neurosurgical practice
115. Thoracic wall invasion secondary to pulmonary aspergillosis
116. Paraplegia due to aspergillosis
117. Aspergillus infection of the central nervous system in patients with acquired immunodeficiency syndrome
118. Aspergillus osteomyelitis in a child treated for acute lymphoblastic leukemia
119. Aspergillus infections of the lumbar disc spaces
120. Aspergillus osteomyelitis: Report of a case and review of the literature
121. Aspergillus discitis: Report of two cases and review of the literature
122. Aspergillus flavus mycetoma and epidural abscess successfully treated with itraconazole
123. Aspergillus spondylodiscitis: Successful conservative treatment in 9 cases
124. Treatment of post-operative Aspergillus fumigatus spondylodiscitis with itraconazole
125. Aspergillus spondylodiscitis: Apropos of 3 cases
126. Aspergillus spondylodiscitis: Apropos of 5 cases
127. Invasive Aspergillus infections in a pediatric hospital: A ten year review
128. Primary cutaneous aspergillosis associated with Hickman intravenous catheters
129. Aspergillus chevalieri (Mangin) Thom and Church: A new opportunistic pathogen of human cutaneous aspergillosis
130. Dermatologic manifestations of infections in neutropenic patients
131. Therapy with ciclopirox lacquer of onychomycosis caused by molds
132. Successful treatment of Aspergillus flavus onychomycosis with oral itraconazole
133. Cure of Aspergillus ustus endocarditis
134. Successful drug therapy in Aspergillus endocarditis
135. Invasive aspergillosis presenting as pericarditis and cardiac tamponade
136. Aspergillus pericarditis: Clinical and pathologic features in the immunocompromised patient
137. Pneumopericardium complicating invasive pulmonary aspergillosis: Case report and review
138. Aspergillus pericarditis: Report of a successfully treated case with tamponade and literature review
139. Isolated cardiac aspergillosis after bone marrow transplantation
140. Aspergillus pancarditis following bone marrow transplantation for chronic myelogenous leukemia
141. Aspergillus myocarditis presenting as myocardial infarction with complete heart block
142. Fungal infections of the heart: Analysis of 51 autopsy cases
143. Acute ureteral colic from an obstructing renal aspergilloma
144. Renal aspergilloma due to Aspergillus flavus
145. Aspergillus peritonitis in peritoneal dialysis: Case report and a review of the literature
146. Aspergillus peritonitis: Therapy, survival, and return to peritoneal dialysis
147. Aspergillus peritonitis in a continuous ambulatory peritoneal dialysis patient: Case report and review of the literature
148. Bowel infarction as the initial manifestation of disseminated aspergillosis
149. Primary lymph node invasive aspergillosis
150. Quandary about treatment of aspergillomas persists
151. Aspergilloma and residual tuberculosis cavities - The result of a resurvey
152. What happens to patients with pulmonary aspergilloma?
153. Serologic monitoring of disease and treatment in a patient with pulmonary aspergilloma
154. Aspergilloma in sarcoid and tuberculosis
155. Pulmonary aspergilloma and AIDS
156. Aspergillosis of the lung - An 18 year experience
157. Pulmonary aspergillomas: Diagnostic and therapeutic consideration
158. Sarcoidosis and aspergilloma: The role of surgery
159. Surgical treatment of pulmonary aspergillomas
160. Pulmonary aspergillomas: An analysis of 41 patients
161. The surgical implications of intracavitary mycetomas (fungus balls)
162. Surgical treatment of pulmonary aspergilloma
163. Pleuropulmonary aspergilloma: Clinical spectrum and result of surgical treatment
164. Pulmonary aspergilloma: Results of surgical treatment
165. Pulmonary aspergilloma: Analysis of prognosis in relation to haemoptysis and survey of treatment
166. Mycetomas in pulmonary sarcoidosis: Nonsurgical management
167. Treatment of hemoptysis by embolization of bronchial arteries
168. Management of massive hemoptysis by bronchial artery embolization
169. Radiotherapy for massive hacmoptysis from an aspergilloma
170. Severe hemoptysis associated with pulmonary aspergilloma: Percutaneous intracavitary treatment
171. Topical treatment of pulmonary aspergilloma by antifungals
172. Intracavitary aspergilloma: Percutaneous injection of amphotericin gelatin solution
173. Amphotericin B in the treatment of saprophytic forms of pulmonary aspergilloma
174. Itraconazole in the treatment of pulmonary aspergilloma and chronic pulmonary aspergillosis
175. European experience with itraconazole in systemic mycoses
176. Treatment of pulmonary aspergilloma with itraconazole
177. Pulmonary aspergillomas treated with corticosteroids
178. Bronchopulmonary aspergillosis
179. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis
180. Allergic bronchopulmonary aspergillosis in corticosteroid-dependent asthmatics
181. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
182. The radiological appearances in allergic broncho-pulmonary aspergillosis
183. Allergic bronchopulmonary aspergillosis: Staging as an aid to management
184. The assessment of immunologic and clinical changes occurring during corticosteroid therapy for allergic bronchopulmonary aspergillosis
185. Five-year follow-up of allergic bronchopulmonary aspergillosis
186. Asthmatic pulmonary eosinophilia: A review of 65 cases
187. Corticosteroid treatment and prognosis in pulmonary eosinophilia
188. Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis
189. Treatment of bronchopulmonary aspergillosis with clotrimazole
190. Trial of ketoconazole in non-invasive pulmonary aspergillosis
191. Trial of ketoconazole in allergic bronchopulmonary aspergillosis
192. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole
193. Allergic bronchopulmonary aspergillosis treated with itraconazole
194. Allergic bronchopulmonary aspergillosis in cystic fibrosis: Role of atopy and response to itraconazole
195. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis
196. Report to the Research Committee of the British Thoracic Association: Inhaled beclomethasone dipropionate in allergic bronchopulmonary aspergillosis
197. Management of allergic bronchopulmonary aspergillosis without maintenance oral corticosteroids: A fifteen-year follow-up
198. Usefulness of inhaled high-dose corticosteroids in allergic bronchopulmonary aspergillosis
199. Mould counts and exacerbations of allergic bronchopulmonary aspergillosis
200. Studies in chronic allergic bronchopulmonary aspergillosis. I. Clinical and physiological findings